Phaim Pharma Ltd

We are a London-based biotechnology company developing a novel therapeutic platform, known as Antigenic Immune Modulation (AIM), designed to cure, improve, halt or prevent autoimmune disease. Our lead drug candidate targets Type 1 Diabetes (T1D), with a pipeline that includes psoriasis, rheumatoid a... Read more